

Stereby certify that this correspondence is being deposited with the U.S. Hestal Service as Express Mail, Airbill No. EU098495674US, in an envelope of correspondence for Patents, Washington, DC 20231, on the late shown below.

bated: February 7, 2003

Signature: Such Harris

Docket No.: HO-P02188US0

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Goran Forsberg, et al

Application No.: 09/900,766

Group Art Unit: 1645

Filed: July 6, 2001

Examiner: Not Yet Assigned

For: NOVEL ENGINEERED SUPERANTIGEN FOR

**HUMAN THERAPY** 

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:

Enclosed are the following items for filing in connection with the above-referenced Patent Application:

- 1. Response to Restriction Requirement
- 2. Return Post Card

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. 10104199 from which the undersigned is authorized to draw.

Dated: February 7, 2003

Respectfully submitted,

Medissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100 Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

PE Project of the temporal of the correspondence of the correspond

Pleoting /#10 2.26.03

Docket No.: HO-P02188US0

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Goran Forsberg, et al

Application No.: 09/900,766

Group Art Unit: 1645

Filed: July 6, 2001 Examiner: Not Yet Assigned

For: NOVEL ENGINEERED SUPERANTIGEN FOR HUMAN THERAPY

## RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed January 14, 2003 (Paper No. 9), Applicants hereby provisionally elect Group III, claims 15-34 and 53-72 for continued examination on their merits without traverse.

The Examiner has also required a species election for Group III. In response to the species election, Applicants hereby provisionally elect the following species: SEE (Staphylococcal enterotoxin) for the antigen, 5T4 for the Fab fragment, lung cancer for the cancer, and IL-2 for the cytokine. Yet further, if SEE is elected, the Examiner has required specific substitutions to be elected. Thus, in response to the specific substitutions of position C and A, Applicants provisionally elect position C substitution 83 and position A substitution 27 to be prosecuted on their merits.

Applicants believe no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. 10104199 from which the undersigned is authorized to draw.

Dated: February 7, 2003

Respectfully submitted,

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)